Filtered By:
Specialty: Cardiology
Drug: Aspirin
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 932 results found since Jan 2013.
EP News: Allied Professionals
In this non-prespecified, post hoc analysis of the AUGUSTUS (The Open-Label, 2 x 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention) trial (Harskamp et al. J Am Coll Cardiol. 2022;79:417-27. PMID-35115097), the authors sought to evaluate whether the risk of bleeding or stroke as assessed by baseline HAS-BLED and CHA2DS2-VASc scores affected the results of the trial.
Source: Heart Rhythm - March 9, 2022 Category: Cardiology Authors: Erica S. Zado Source Type: research
The WOEST 2 registry : A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention
CONCLUSIONS: Patients on combined oral anticoagulation and antiplatelet therapy undergoing PCI are elderly and have both a high bleeding and ischaemic risk. Over time, a NOAC plus clopidogrel became the preferred treatment. The rate of thrombotic and bleeding events was not significantly different between patients on triple or dual therapy or between those on VKAs versus NOACs.PMID:35230636 | DOI:10.1007/s12471-022-01664-0
Source: Netherlands Heart Journal - March 1, 2022 Category: Cardiology Authors: A J W M de Veer N Bennaghmouch W L Bor J P R Herrman M Vrolix M Meuwissen T Vandendriessche T Adriaenssens B de Bruyne M Magro W J M Dewilde J M Ten Berg Source Type: research
An Updated Review of Cardiovascular Events in Giant Cell Arteritis
J Clin Med. 2022 Feb 15;11(4):1005. doi: 10.3390/jcm11041005.ABSTRACTGiant cell arteritis (GCA) is a systemic vasculitis with a direct and indirect increased risk of acute and chronic vascular events, affecting large and medium vessels, and responsible for most of the morbidity and mortality of this disease. We aimed in this review to provide an updated synthesis of knowledge regarding cardiovascular events observed in GCA. By definition, GCA patients are over 50 and often over 70 years old, and subsequently also present age-related cardiovascular risk factors. In addition, the systemic and vascular inflammation as well as...
Source: Atherosclerosis - February 25, 2022 Category: Cardiology Authors: Hubert de Boysson Achille Aouba Source Type: research
When and How to Combine Antiplatelet and Anticoagulant Drugs?
Hamostaseologie. 2022 Feb;42(1):73-79. doi: 10.1055/a-1724-4922. Epub 2022 Feb 23.ABSTRACTAntiplatelet and anticoagulant drugs work at different places in the coagulation system. Antiplatelet drugs are usually indicated in patients with atherosclerosis. Anticoagulant drugs are mostly used in patients with atrial fibrillation, venous thromboembolism, or technical heart valves. In some clinical situations, combination of antiplatelet and anticoagulant therapy can be indicated. The most recent situations are a more intensive antithrombotic therapy for risk reduction in patients with atherosclerosis and temporary addition of a...
Source: Atherosclerosis - February 23, 2022 Category: Cardiology Authors: Christine Espinola-Klein Source Type: research
State-of-the-art-mini review: Dual pathway inhibition to reduce arterial and venous thromboembolism
Thromb Haemost. 2022 Feb 21. doi: 10.1055/a-1778-1083. Online ahead of print.ABSTRACTVenous thromboembolism (VTE) and arterial thromboembolism (ATE) are linked by the common mechanism of thrombin generation. Historically these entities have been treated as separate pathophysiologic processes requiring different treatments: VTE, as the formation of fibrin-/coagulation-factor-derived thrombus in low flow vasculature, requiring anticoagulants; versus ATE, as largely platelet-derived thrombus in high flow vasculature, requiring antiplatelet agents. Observational studies have elucidated shared risk factors and co-morbidities pr...
Source: Atherosclerosis - February 21, 2022 Category: Cardiology Authors: Mark Goldin Ioannis Koulas Jeffrey I Weitz Alex Spyropoulos Source Type: research
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment
Lancet Neurol. 2022 Feb 7:S1474-4422(21)00376-8. doi: 10.1016/S1474-4422(21)00376-8. Online ahead of print.ABSTRACTIntracranial atherosclerotic stenosis (ICAS) is one of the most frequent causes of stroke worldwide and confers one of the greatest risks of recurrent stroke compared with other causes of stroke. Asymptomatic ICAS is increasingly recognised as a risk factor for silent brain infarctions and dementia, magnifying the global burden of ICAS. Although ICAS is a lumen-based diagnosis, newer diagnostic imaging techniques, such as high-resolution MRI, might help to identify high-risk population subgroups to test interv...
Source: Atherosclerosis - February 10, 2022 Category: Cardiology Authors: Jose Gutierrez Tanya N Turan Brian L Hoh Marc I Chimowitz Source Type: research
Posterior Circulation Ischaemic Stroke
Am J Med Sci. 2022 Jan 29:S0002-9629(22)00030-1. doi: 10.1016/j.amjms.2021.10.027. Online ahead of print.ABSTRACTPosterior circulation ischaemic stroke (PCIS) is a disease of high burden. They account for 20-25% of all ischaemic strokes. However, it is relatively under-researched and requires more clinical attention, since it carries worse functional outcomes. Vertigo, visual disturbances and sensory/motor disturbances are found in PCIS. Large artery atherosclerosis and embolism are main causes of PCIS, while there is growing evidence that vertebrobasilar dolichoectasia is a key association. Hypertension is the commonest r...
Source: Atherosclerosis - February 1, 2022 Category: Cardiology Authors: Mr Alexander Ng Source Type: research
Initial practice of left atrial appendage closure device in Japan; single-center experience
CONCLUSIONS: In this initial Japanese experience, LAAC therapy for high bleeding risk patients with NVAF seems feasible. Optimal antithrombotic regimens are warranted for better clinical outcomes.PMID:35094892 | DOI:10.1016/j.jjcc.2022.01.004
Source: Journal of Cardiology - January 31, 2022 Category: Cardiology Authors: Masato Fukunaga Akihiro Isotani Shinichi Shirai Naoto Murakami Miho Nakamura Takashi Morinaga Kenichi Ishizu Kazuki Kitano Tatsuhiro Kataoka Masaomi Hayashi Kenichi Hiroshima Kenji Ando Source Type: research
